Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A Administered in Adults 18 to 60 Years of Age

Next Previous
Search
Trial Profile

An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A Administered in Adults 18 to 60 Years of Age

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 03 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 3277509A (Primary) ; GSK 3277510A (Primary)
  • Indications Influenza A virus H7N9 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 16 Jun 2016 Status changed from not yet recruiting to withdrawn prior to enrolment due to scientifically legitimate reasons not related to safety or efficacy of the vaccine.
    • 31 Jul 2014 Planned End Date changed from 1 Dec 2015 to 1 Feb 2017 as reported by ClinicalTrials.gov record.
    • 31 Jul 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Feb 2016 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top